By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors JIN, YIFENG; WU, QI; ZHANG, TAIPING; MA, XIAOYAN; XUAN, JI, filed on January 27, 2014, was made available online on November 17, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent ap
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week CSL Behring announced positive results from AEGIS-I, a Phase 2 b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I infusion therapy. Results from AEGIS-I were presented today at the American Heart Association Scientific Sessions in New Orleans
By a News Reporter-Staff News Editor at Drug Week AbbVie, a global biopharmaceutical company, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for HUMIRA for the treatment of active moderate to severe hidradenitis suppurativa in adolescents from 12 years of age wi
The Amyotrophic Lateral Scloerosis Association issued the following news release:. The ALS Association, in partnership with ALS Finding a Cure and the Northeast ALS Consortium, is pleased to announce $1 million in funding to support a new ALS clinical trial to test the efficacy of the experimental drug RNS60 in reducing inflammation that may hasten
Amgen and Allergan plc. today announced the submission of a Marketing Authorization Application to the European Medicines Agency for ABP 215, a biosimilar candidate to Avastin . "The submission of ABP 215 to the EMA is an important milestone as Amgen seeks to expand our oncology portfolio," said Sean E. Harper, M.D., executive vice president o
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim results from two ongoing Phase 1 b open-label, dose-escalation clinical trials of APL-2, a complement C3 inhibitor, in paroxysmal nocturnal hemoglobinuria. PNH is a rare, acquired, potential
WHITEHOUSE STATION- Shares of Aradigm Corp. plunged over 56% on Thursday after two phase III studies evaluating Pulmaquin for the chronic treatment of Non-Cystic Fibrosis Bronchiectasis patients with lung infections with Pseudomonas aeruginosa delivered a mixed bag of results. The company will review the next steps towards an application for approv
Workshop to occur on Sunday December 4 at 11:00 am PT Breda, the Netherlands/ Ghent, Belgium- argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will provide updates on its two lead programs,..
Basel, Switzerland, December 02, 2016- Basilea Pharmaceutica Ltd. announced today the expansion of its ongoing oncology drug candidate BAL101553 clinical phase 1/ 2 a oral formulation study. Achim Kaufhold, Basilea's Chief Medical Officer, commented: "We are excited to explore BAL101553 in a separate glioblastoma study arm to our ongoing phase 1/
By a News Reporter-Staff News Editor at Drug Week CEL-SCI Corporation, a biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, announced new preclinical data that demonstrate its investigational new drug candidate CEL-4000 has the potential for
-Cellectar Biosciences, Inc., an oncology-focused, clinical stage biotechnology company, today provides a data update on the first two cohorts of the companys Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. The clinical benefit rate for this study is 80 percent despite patients receiving an average of fou
OSAKA, Japan& CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited:. Takeda Pharmaceutical Company Limited and Lightstone Ventures today announced the launch of Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology, created i
Clinical Trials Imaging Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015- 2023 Albany, NY 12/02/2016 Over the past three decades, imaging market has undergone an extensive transformation both in clinical and non-clinical arenas. Clinical imaging is now an important part of the expensive research and development
Release date- 01122016- Melbourne Australia-CSL has today announced that it has progressed three new therapies into first-in-human studies in Australia. CSL Commits to New Phase I Clinical Trials in Australia. We are very pleased to move three projects into clinical trials over a 12 month period, all of which will be conducted in Australia.
The new center will provide office and laboratory space to facilitate the company's aggressive plans for developing products for FDA approval under its wholly owned subsidiary, RM Therapeutics. The new space is located in Woburn, less than mile from the company's headquarters in Wilmington. CutisPharma has recently undertaken several significant...
-Cytokinetics, Inc. today announced the activation of the first clinical site and the start of GALACTIC-HF, the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil which is being conducted by Amgen, in collaboration with Cytokinetics. Coincident with the start of the trial, Amgen will make a $26.7 million milestone payment to Cytok
On November 29, 2016, Emmaus Life Sciences, Inc., issued a press release announcing that the U.S. Food and Drug Administration has set a PDUFA date of July 7, 2017 for a decision on the Company's New Drug Application. The company also announced it will present data from a subgroup analysis of its Phase 3 clinical trial with Pharmaceutical grade L-g
"Enbrel Biosimilars Clinical Trial Insight" report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on October 23, 2012, b
Dec. 01 Florida Atlantic University will license the technology of a life science company in its entrepreneurial program a move that could potentially bring millions of dollars in royalties to the university. "This licensing agreement is a testament to Ken Dawson-Scully's world-class research here at Florida Atlantic University," said Daniel F
Florida Atlantic University will license the technology of a life science company in its entrepreneurial program a move that could potentially bring millions of dollars in royalties to the university. "This licensing agreement is a testament to Ken Dawson-Scully`s world-class research here at Florida Atlantic University," said Daniel Flynn, FAU`s
Release date- 01122016- Application seeks to expand ABILIFY MAINTENA label to include maintenance treatment for bipolar I disorder. Otsuka Pharmaceutical Co., Ltd. and Lundbeck announced the U.S. Food and Drug Administration has determined that the supplemental New Drug Application for the expanded labeling of ABILIFY MAINTENA for the maintenance..
Fortress Biotech, Inc. is not putting all its eggs in one basket. This is a biopharmaceutical company with multiple revenue streams and a profuse product portfolio so diversified that Harry Markowitz, the father of modern portfolio theory, might tip his hat to the way the company has sought to mitigate developmental risks. Fortress diverse produ
By a News Reporter-Staff News Editor at Genomics& Genetics Weekly Genexine, a clinical stage biotechnology company developing innovative biologics, announced that it has entered into a clinical research collaboration with Merck& Co., Inc., Kenilworth, NJ, USA, for the assessment of Genexine's GX-188E, HPV therapeutic DNA vaccine, in combination w
Basilea Pharmaceutica AG/ Basilea expands oncology drug candidate BAL101553 clinical phase 1/ 2 a oral study to include glioblastoma patients. Basel, Switzerland, December 02, 2016- Basilea Pharmaceutica Ltd. announced today the expansion of its ongoing oncology drug candidate BAL101553 clinical phase 1/ 2 a oral formulation study. Achim Kaufhold,.
Impel NeuroPharma received $21 M in the initial tranche with the remaining $15 M to be received upon accomplishment of certain development and business milestones. Impel NeuroPharma is developing a pipeline of drug-device combination products built upon its Precision Olfactory Delivery? nasal delivery platform. The nasal cavity is a vastly...